While β-site amyloid precursor protein-cleaving enzyme-1 (BACE1) inhibitors decrease amyloid-β levels, they also increase BACE1 protein levels by preventing degradation, which may be the reason they have not resulted in cognitive improvements in people with Alzheimer’s disease (AD).
Why this matters
Development of BACE1 inhibitors has been halted in clinical trials because they have failed to prevent cognitive decline in people with AD.
It is important to study BACE1 inhibitor action to understand why this investigational class is not effective and possibly improve potential therapies.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.